Vertex's revenue has expanded steadily from $161.1M in Q2 2024 to $213.3M in Q3 2026, with year-over-year growth holding near 10.5% to 11.1% in recent quarters, suggesting durable demand for its tax software.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.26+17.0% vs $0.22 | $213M+1.7% vs $210M |
Q3 2026 Aug 3, 2026 | $0.20+4.8% vs $0.19 | $204M+0.9% vs $202M |
Q2 2026 May 7, 2026 | $0.17+6.3% vs $0.16 | $197M+0.9% vs $195M |
Q1 2026 Feb 11, 2026 | $0.17+0.0% vs $0.17 | $195M+0.2% vs $194M |
Bristol Myers Squibb is an established pharmaceutical powerhouse with a high-yield dividend and a focus on expanding its portfolio through strategic oncology alliances. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while diversifying into gene editing and treatments for acute pain.
Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.
Vertex Inc (NASDAQ:VERX) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.
Vertex NASDAQ: VERX raised its full-year revenue and earnings guidance after reporting third-quarter revenue growth of 11% and a nearly 50% increase in adjusted earnings before interest, taxes, depreciation and amortization, or EBITDA.
Benchmark VERX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vertex, Inc. (VERX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.08 | $2.76B | -58.77 | 12.25% | -5.83% | -20.33% | — | |
| $0.82 | $3.89M | -0.01 | -29.45% | -267.2% | — | — | |
| $47.73 | $12.51B | 64.62 | 21.28% | 5.95% | 17.64% | 0.47% | |
| $341.50 | $93.41B | 20.34 | 13.9% | 21.29% | 23.42% | 1.42% | |
| $303.35 | $121.26B | 26.65 | 6.74% | 20.33% | 75.85% | 2.17% | |
| $173.15 | $9.27B | 33.29 | 11.04% | 15.39% | 24.03% | — |
Vertex, Inc. (VERX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vertex, Inc. (VERX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Aug 3, 2026·SEC
Jun 11, 2026·SEC
Get notified when VERX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vertex, Inc. (VERX) stock FAQ — growth, dividends, profitability & financials explained
Vertex, Inc. (VERX) reported $808.6M in revenue over the trailing twelve months. Revenue was $748.4M in fiscal year 2025. That is 175% more than the $272.4M of fiscal year 2018.
Vertex, Inc. (VERX) grew revenue by 10.4% over the trailing twelve months, compared with the twelve months before.
No. Vertex, Inc. (VERX) reported a net loss of $47.1M over the trailing twelve months.
Vertex, Inc. (VERX) had a return on equity (ROE) of -20.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Vertex, Inc. (VERX) generated $28.3M in free cash flow over the trailing twelve months.
